367 related articles for article (PubMed ID: 33606661)
1. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
5. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.
Julián MT; Ballesta S; Pera G; Pérez-Montes de Oca A; Soldevila B; Caballería L; Morillas R; Expósito C; Martínez-Escudé A; Puig-Domingo M; Franch-Nadal J; Torán P; Cusi K; Julve J; Mauricio D; Alonso N
Front Endocrinol (Lausanne); 2022; 13():1051958. PubMed ID: 36714592
[TBL] [Abstract][Full Text] [Related]
6. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
7. Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
Kuchay MS; Choudhary NS; Gagneja S; Mathew A; Bano T; Kaur P; Bahadur B; Singh MK; Gill HK; Wasir JS; Sud R; Mishra SK
J Gastroenterol Hepatol; 2021 Nov; 36(11):3204-3211. PubMed ID: 34160089
[TBL] [Abstract][Full Text] [Related]
8. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
10. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
[TBL] [Abstract][Full Text] [Related]
11. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
12. Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages.
Shi YW; Wang QY; Zhao XY; Sun YM; Kong YY; Ou XJ; Jia JD; Wu SS; You H
J Dig Dis; 2020 May; 21(5):279-286. PubMed ID: 32336033
[TBL] [Abstract][Full Text] [Related]
13. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
Ciardullo S; Perseghin G
Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
[TBL] [Abstract][Full Text] [Related]
14. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
15. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection.
Krahn T; Martel M; Sapir-Pichhadze R; Kronfli N; Falutz J; Guaraldi G; Lebouche B; Klein MB; Wong P; Deschenes M; Ghali P; Sebastiani G
J Infect Dis; 2020 Aug; 222(5):787-797. PubMed ID: 32249283
[TBL] [Abstract][Full Text] [Related]
17. Dysglycemia in young women attenuates the protective effect against fatty liver disease.
Pérez-Montes de Oca A; Julián MT; Pera G; Caballería L; Morillas R; Torán P; Expósito C; Franch-Nadal J; Mauricio D; Alonso N
Front Endocrinol (Lausanne); 2022; 13():971864. PubMed ID: 36479218
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
Martínez-Ortega AJ; Piñar Gutiérrez A; Lara-Romero C; Remón Ruiz PJ; Ampuero-Herrojo J; de Lara-Rodríguez I; Romero-Gómez M; García Luna PP; Soto-Moreno A
Nutr Hosp; 2022 Oct; 39(5):1012-1018. PubMed ID: 36134588
[TBL] [Abstract][Full Text] [Related]
19. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
20. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
